10 Fr S-Type Plastic Pancreatic Stents in Chronic Pancreatitis Are Effective for the Treatment of Pancreatic Duct Strictures and Pancreatic Stones

Abstract EN

Aim.

Endoscopic pancreatic stenting for refractory pancreatic duct strictures associated with impacted pancreatic stones in chronic pancreatitis cases has yielded conflicting results.

We retrospectively evaluated the efficacy of endoscopic treatment in chronic pancreatitis patients with pancreatic duct strictures.

Methods.

Pancreatic sphincterotomy, dilatation procedures, pancreatic brush cytology, and pancreatic juice cytology were routinely performed, and malignant diseases were excluded.

After gradual dilatation, a 10 Fr plastic pancreatic stent was inserted.

The stents were replaced every 3 months and removed after the strictures were dilated.

Statistical analyses were performed to determine the risk of main pancreatic duct restenosis.

Results.

Endoscopic pancreatic stents were successfully placed in 41 of a total of 59 patients (69.5%).

The median duration of pancreatic stenting was 276 days.

Pain relief was obtained in 37 of 41 patients (90.2%).

Seventeen patients (41.5%) had recurrence of main pancreatic duct stricture, and restenting was performed in 16 patients (average placement period 260 days).

During the follow-up period, pancreatic cancer developed in three patients (5.1%).

Multivariate analysis revealed that the presence of remnant stones after stenting treatment was significantly associated with a higher rate of main pancreatic duct restenosis (p=0.03).

Conclusion.

The use of 10 Fr S-type plastic pancreatic stents with routine exchange was effective for both short-term and long-term outcomes in chronic pancreatitis patients with benign pancreatic duct strictures and impacted pancreatic stones.